NOVO-NORDISK A/S-SPONS ADR
NVONYSEEarnings Nov 4US Equity
$47.17▼ $0.55 (−1.17%)
Live1h—
24h▼ 1.2%
7d—
14d—
30d—
1y—
🏦Market Cap
$159.91B
Mid Cap
📈Revenue Growth (YoY)
+5.6%
Slowing
📊Gross Margin
80.7%
High
💵FCF Margin
25.8%
Strong
⚖️P/S Ratio
4.1x
Fair
Otter Score
46
Weak
No chart data available for NVO.
Trading Snapshot
- Day Range
- $46.97 – $48.04
- 52-Week Range
- —
- Volume
- $5.71B
- Avg Volume
- $4.84B
- Shares Outstanding
- 3.39B
- Next Earnings
- Sep 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $309.06B
- Last Q Revenue
- $78.49B
- P/E Ratio
- 11.6
- P/S Ratio
- 4.1x
- EPS (TTM)
- —
- Dividend Yield
- 3.84%
Why Investors Own NVO
- ✓High-growth profile — revenue up +28.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 27% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$309.06B▲ +34.0% YoY
Gross Margin (TTM)
26.8%▲ +1.9% YoY
Operating Income (TTM)
$70.47B▲ +34.0% YoY
Free Cash Flow (TTM)
$42.34B▲ +34.0% YoY
About NOVO-NORDISK A/S-SPONS ADR
Pharma with leading GLP-1 franchise (Ozempic, Wegovy).
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
46/100
Analyst Price Target
ⓘAverage Target
$56.70
▲ +20.2% Upside
High Target$63.38
Low Target$47.06
Based on 36 analysts
Latest News & Updates
🚀
CNBC·2h ago
NOVO-NORDISK A/S-SPONS ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift NVO price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
NOVO-NORDISK A/S-SPONS ADR announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.